AbbVie Inc is to expand its neuroscience pipeline with the acquisition of Cerevel Therapeutics LLC of Cambridge, US, which has a clinical-stage product for schizophrenia targeting a receptor that regulates signalling in the brain. Announced on 6 December, the deal is valued at $8.7 billion and comes only a week after AbbVie disclosed plans to buy ImmunoGen Inc, a company with antibody-drug conjugate products for cancer. The ImmunoGen deal is valued at $10.1 billion.
